http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2683184-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 |
| filingDate | 2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_601c19976e89d0375a62f5cbdd65c1c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f9a41446ed9e62072a012bc0623c090 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_419f28913db0c4b653ec69a5c26e84df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_545d7b99accedceb17151bc902cb29f0 |
| publicationDate | 2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2683184-T3 |
| titleOfInvention | GLyT1 inhibitors for use in the treatment of blood disorders |
| abstract | A Glyt1 inhibitor, selected from [4- (2-fluoro-4-methanesulfonyl-phenyl) -piperazin-1-yl] - (2-isopropoxy-5-methanesulfonyl-phenyl) -methanone [5-methanesulfonyl-2- ( 2,2,2-Trifluoro-1-methyl-ethoxy) -phenyl] - [4- (5-trifluoromethyl-pyridin-2-yl) -piperazin-1-yl] -methanone 4-isopropoxy-N-methyl-3 - [4- (4-Trifluoromethyl-phenyl) -piperazin-1-carbonyl] -benzenesulfonamide [4- (3-fluoro-5-trifluoromethyl-pyridin-2-yl) -piperazin-1-yl] - [5-methanesulfonyl -2 - ((S) -2,2,2-trifluoro-1-methyl-ethoxy) -phenyl] - methanone [5-methanesulfonyl-2 - ((S) -2,2,2-trifluoro-1-methyl -ethoxy) -phenyl] - (3-trifluoromethyl-5,7-dihydro-pyrrolo [3,4-b] pyridin-6-yl) -methanone [5-methanesulfonyl-2 - ((S) -2,2, 2-Trifluoro-1-methyl-ethoxy) -phenyl] - (6-trifluoromethyl-1,3-dihydro-pyrrolo [3,4-c] pyridin-2-yl) -methanone or [5-methanesulfonyl-2- ( (S) -2,2,2-Trifluoro-1-methyl-ethoxy) -phenyl] - (5-methoxy-6-trifluoromethyl-1,3-dihydro-isoindol-2-yl) -methanone for use in treatment or prevention of blood disorders, selected from sickle cell disease, thalassemia and syndrom and iron overload, in particular for the treatment of hereditary hemochromatosis. |
| priorityDate | 2014-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 324.